XXXX -associated @entity4810 .

@entity1 @entity1665 @entity249 @entity4810 @entity585 @entity6660 @entity3893
OBJECTIVE: To describe a male @entity1 with @entity585 -associated @entity249 . DESIGN: Case report. SETTING: Tertiary-care clinic for @entity4810 . @entity1 (S): A @entity1 with @entity3893 who had been taking @entity585 (1-mg dose) for 1 year for @entity1665 . He had been diagnosed with @entity6660 5 years before. INTERVENTION(S): Discontinuation of @entity585 . MAIN OUTCOME MEASURE(S): Improvement of semen parameters. RESULT(S): After cessation of @entity585 , the @entity1 's semen volume increased immediately, and sperm concentration was up to more than 10   10(6)/mL 16 weeks after stopping @entity585 . He is now trying to achieve pregnancy by intrauterine insemination. CONCLUSION(S): Cessation of @entity585 improved spermatogenesis and allowed the couple to attempt less-invasive fertility therapy. In this case, the @entity1 had impaired spermatogenesis before he started the drug. In such @entity1 , the drug may further decrease spermatogenesis. We suggest that drug cessation could be taken into consideration for infertile male @entity1 with impaired semen parameters who are taking @entity585 at a 1-mg dose.
